We develop and produce fully functioning human cells in industrial quantities to precise specifications. Our proprietary products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). Our products provide standardized, easy-to-use, cost-effective access to the human cell, the smallest fully functioning operating unit of human biology. We market our products for use in life science in vitro research and development as well as applied product testing, stem cell banking and in vivo cellular therapeutics. We are also in the process of developing human cells as cellular therapeutics. Our products are based on our iPSC technology. An iPSC is a cell that has the ability both to replicate indefinitely and to be transformed into any cell type in the human body. Our iPSCs are produced from ordinary blood or skin using proprietary techniques that expand upon those pioneered by our founder Dr. James A. Thomson. Once we produce an iPSC, it can be banked indefinitely and becomes a renewable source of starting material for our iCell and MyCell products.
Company profile
Ticker
ICEL
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Amgen • GE Vernova • Gilead Sciences • Apollo Global Management • ADT • Li Auto • Informatica • Burford Capital Limited • NIO • Opendoor ...
SEC CIK
Corporate docs
IRS number
261737267
Latest filings (excl ownership)
15-12B
Securities registration termination
11 May 15
EFFECT
Notice of effectiveness
11 May 15
POS AM
Prospectus update (post-effective amendment)
8 May 15
S-8 POS
Registration of securities for employees (post-effective amendment)
8 May 15
S-8 POS
Registration of securities for employees (post-effective amendment)
8 May 15
S-8 POS
Registration of securities for employees (post-effective amendment)
8 May 15
25-NSE
Exchange delisting
1 May 15
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1 May 15
SC 14D9/A
Tender offer solicitation (amended)
1 May 15
SC TO-T/A
Third party tender offer statement (amended)
1 May 15
Latest ownership filings
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|